Title : Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.

Pub. Date : 2020 Oct 16

PMID : 33081092






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In our study, we investigated the MEK inhibitor selumetinib and PI3K/mTOR dual inhibitor BEZ235 alone and in combination in BRAF-only mutant and BRAF + PI3K/PTEN double mutant cancer cells using short- and long-term 2D viability assays, spheroid assays, and immunoblots. AZD 6244 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens
2 In the 2D assays, selumetinib was more effective on BRAF-only mutant lines when compared to BRAF + PI3K/PTEN double mutants. AZD 6244 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens